Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. - Wikidata - awgldk - TriplyDB

Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme.

Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme.

http://www.wikidata.org/entity/Q34246882

about

Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review Digitalis for treatment of heart failure in patients in sinus rhythm Digitalis for treatment of heart failure in patients in sinus rhythm Differential clinical profile of candesartan compared to other angiotensin receptor blockers Epidemiology and risk profile of heart failure Standards of medical care in diabetes--2012 Determinants of persistence in hypertensive patients treated with irbesartan: results of a postmarketing survey.The Different Therapeutic Choices with ARBs. Which One to Give? When? Why?Renin-angiotensin system blockade: Its contribution and controversy Optimization of cardiac metabolism in heart failure Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients Modulation of glucose metabolism by the renin-angiotensin-aldosterone system Sacubitril/valsartan in heart failure: latest evidence and place in therapy Cardiac remodelling and RAS inhibition Clinical trials update from the European Society of Cardiology: CHARM, BASEL, EUROPA and ESTEEM Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases Pharmacological prevention of atherothrombotic events in patients with peripheral arterial disease A reappraisal of loop diuretic choice in heart failure patients Pharmacological effects of AVE 0991, a nonpeptide angiotensin-(1-7) receptor agonist Renin-Angiotensin-aldosterone system in diabetes and hypertension Differences in efficacy and safety of pharmaceutical treatments between men and women: an umbrella review Oral administration of an angiotensin-converting enzyme 2 activator ameliorates diabetes-induced cardiac dysfunction Angiotensin receptor blockers and risk of cancer: cohort study among people receiving antihypertensive drugs in UK General Practice Research Database Standards of medical care in diabetes--2013 Comparing angiotensin II receptor blockers on benefits beyond blood pressure RAAS inhibitors and cardiovascular protection in large scale trials.AT1A angiotensin receptors in the renal proximal tubule regulate blood pressure.A current evaluation of the safety of angiotensin receptor blockers and direct renin inhibitors Angioedema related to Angiotensin inhibitors.Does outcome reporting bias "cause" cancer? Risks associated with hidden data on Angiotensin receptor blockers.Influence of systolic blood pressure on clinical outcomes in elderly heart failure patients treated with nebivolol: data from the SENIORS trial.Pulmonary artery pressure-guided heart failure management: US cost-effectiveness analyses using the results of the CHAMPION clinical trial More evidence on blocking the renin-angiotensin-aldosterone system in cardiovascular disease and the long-term treatment of hypertension: data from recent clinical trials (CHARM, EUROPA, ValHEFT, HOPE-TOO and SYST-EUR2).Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM-study programme.Combined Angiotensin Receptor Modulation in the Management of Cardio-Metabolic Disorders Survival trends in men and women with heart failure of ischaemic and non-ischaemic origin: data for the period 1987-2003 from the Swedish Hospital Discharge Registry.Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program Cardiovascular outcomes in high-risk patients without heart failure treated with ARBs: a systematic review and meta-analysis.Standards of medical care in diabetes--2010.Management of hypertension with fixed dose combinations of candesartan cilexetil and hydrochlorothiazide: patient perspectives and clinical utility

P2860

Q22242077-C6EC4DA3-B2D9-4A7B-82E9-F3B53B11BE2D Q24194992-29CAE09D-FBF4-47A4-8B26-A3E13DAFFC8D Q24247158-AE11255B-3962-4DC4-9D6B-9BABF135559A Q24613321-8B3D4174-04AE-4131-9D5B-94A75AF9D566 Q24630778-E060E1AB-B8F7-4E4D-8294-0155F97C2440 Q24632533-1A7517E5-74F8-4A74-99AE-5A88DBC4EAAF Q24814563-801BA559-C012-4D2A-8D9B-4C790A7544C9 Q26768696-B39EF4BA-F216-4411-A2B8-AFD1E7D347D8 Q26827221-3C84AB50-34E9-4E26-ABC5-F60B462106CA Q27023021-C55ABAD3-CBCE-459D-A043-217D05D4FDD0 Q27023161-E745511D-319A-4568-8C75-2E96E15DFF48 Q27026157-21134299-DF64-4C82-B821-23E0B649C733 Q28070191-9D96E60F-486A-4ED7-B3E5-11E763414F02 Q28076749-F5BE7602-FCA6-410E-9F9C-6306DEAA1EE7 Q28166022-027DB32E-1B44-411C-8B5A-AAD32B3A6345 Q28182631-79D6CFCD-2D4E-4FEB-ADFF-63A37AAF5533 Q28220999-AA0C8E13-B3BD-44DA-8638-39B01055414A Q28258044-5A03D0B1-5C0D-4493-926F-51DC5E9F530B Q28282619-08112310-2A0B-4116-A7AA-C6C92429B899 Q28308222-20E53CAC-5CD4-4624-9155-7A8058A63F88 Q28474985-58008BB5-192B-4A92-9C1D-CBBB0511509B Q28569684-F7DC23A9-48A6-4FD8-AF3D-EB29F0176D64 Q28730234-7EC3E99B-FE31-478C-9A7F-63F1B18AC540 Q29620309-79E8674D-EEB2-4548-941B-6124ED603421 Q30360678-25980BCB-6D83-4958-AEB6-EAB7A2FEE39F Q30424541-620BF572-FEC9-46A6-B979-B7367A5FA38D Q30427451-BCDE6766-9651-4CD9-92B3-75CCCA24C303 Q30432209-14988757-E837-4781-8558-E563AB2849DC Q30458886-D0DB4BFD-2788-4010-94EE-D8212B5866C9 Q30576331-F0D71479-45E5-42A7-BA2D-CE35E3A7B1C4 Q30837563-61CD1F7E-872B-4C8B-BAEC-DBE23EAE1494 Q30851193-F37ABEF2-34EA-463F-8605-0D125F16EBD1 Q30882854-E9070B6F-4316-4E58-BF19-F47FFF2CB850 Q31115364-44549AC5-7089-4FA0-B614-34D40EE56946 Q33166521-B6EE4416-256D-4CCB-907D-04F02D5F13AD Q33395934-ADE6D972-E2DD-4818-A601-B66F24090CDC Q33402824-7A4158BC-9C4B-4FB6-88B1-BE4B7E6181BE Q33403831-FC965919-1E79-43AE-B64F-A209BDC79CC7 Q33554238-940C3724-7A9C-4B95-AFF5-ABE18D0CE1E6 Q33571219-12325EB3-0D90-456F-94E6-B5DBF6FEEC40

P2860

Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme.

http://www.wikidata.org/entity/Q34246882

description

2003 nî lūn-bûn

@nan

2003 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年学术文章

@wuu

2003年学术文章

@zh-cn

2003年学术文章

@zh-hans

2003年学术文章

@zh-my

2003年学术文章

@zh-sg

2003年學術文章

@yue

name

Effects of candesartan on mort ...... : the CHARM-Overall programme.

@ast

Effects of candesartan on mort ...... : the CHARM-Overall programme.

@en

Effects of candesartan on mort ...... : the CHARM-Overall programme.

@nl

type

label

Effects of candesartan on mort ...... : the CHARM-Overall programme.

@ast

Effects of candesartan on mort ...... : the CHARM-Overall programme.

@en

Effects of candesartan on mort ...... : the CHARM-Overall programme.

@nl

prefLabel

Effects of candesartan on mort ...... : the CHARM-Overall programme.

@ast

Effects of candesartan on mort ...... : the CHARM-Overall programme.

@en

Effects of candesartan on mort ...... : the CHARM-Overall programme.

@nl

P1433

Q34246882-9BE8ED91-81E6-496E-BEBF-B438A4EED6A4

P1476

Q34246882-D0BF91AB-AC34-478A-8DC0-ABDDC25C73F8

P2093

Q34246882-014DF912-D8F9-4514-B6B3-AC379C56912F

Q34246882-572B081F-D68F-4CE6-9B42-1BEC2CE71B45

Q34246882-864310DD-7AD8-4512-90C9-39D62F18BD77

Q34246882-890A77D8-B2AF-48EA-87D8-F5BC1D4EFCCC

Q34246882-9ACDA57E-1206-4622-B808-B846CA3EE7BB

Q34246882-9BA7813A-BE43-44DF-842C-43F21C99312A

Q34246882-A10ABC0D-FCAD-4ED6-8A4A-9EEB46D3DA14

Q34246882-F9995AFE-65DA-4FAD-A829-CDBEE67984B2

P304

Q34246882-1DDC4120-153E-4C38-A145-53000C0CC8F6

P31

Q34246882-597108AB-19A6-4F1D-BEA9-36707F6C5D3B

P356

Q34246882-865E9941-B55C-4CF2-A657-70FD3F73A112

P407

Q34246882-42FA34DF-E5F3-4243-B4CC-9BA73C9E2795

P433

Q34246882-3243AC6F-07DD-4F8B-B7A4-C6B1E7E0DDBD

P478

Q34246882-D7354A50-FBF3-417A-A9CE-ABA17F6C4F26

P50

Q34246882-62F43470-5197-4065-A730-B0AC00E758CF

Q34246882-7D02F98C-80E2-4E2F-902A-371732BAC513

Q34246882-ECDF0247-A8A5-43CE-AA87-91C3C3E239E9

P577

Q34246882-433484BC-0798-4265-A773-F0829007957B

P698

Q34246882-E3F2B042-C327-498A-A206-F46E720BD14D

P921

Q34246882-38ABEB2C-BFC5-49DF-9098-A850EE19328F

Q34246882-DF7EB8B4-54EB-46C5-9EF1-14DC27FB15CF

P356

S0140-6736(03)14282-1

P1433

P1476

Effects of candesartan on mort ...... : the CHARM-Overall programme.

@en

P2093

Bertil Olofsson

http://www.w3.org/2001/XMLSchema#string

CHARM Investigators and Committees

http://www.w3.org/2001/XMLSchema#string

Eric L Michelson

http://www.w3.org/2001/XMLSchema#string

Jan Ostergren

http://www.w3.org/2001/XMLSchema#string

John J V McMurray

http://www.w3.org/2001/XMLSchema#string

Marc A Pfeffer

http://www.w3.org/2001/XMLSchema#string

Peter Held

http://www.w3.org/2001/XMLSchema#string

Stuart Pocock

http://www.w3.org/2001/XMLSchema#string

P304

759-766

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S0140-6736(03)14282-1

http://www.w3.org/2001/XMLSchema#string

P407

P433

9386

http://www.w3.org/2001/XMLSchema#string

P478

362

http://www.w3.org/2001/XMLSchema#string

P50

Christopher B. Granger

P577

2003-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

13678868

http://www.w3.org/2001/XMLSchema#string

P921